Stay updated on Yttrium90 Ipilimumab Nivolumab in Uveal Melanoma Clinical Trial
Sign up to get notified when there's something new on the Yttrium90 Ipilimumab Nivolumab in Uveal Melanoma Clinical Trial page.

Latest updates to the Yttrium90 Ipilimumab Nivolumab in Uveal Melanoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page's revision label was updated from v3.6.3 to v3.6.4, indicating a small backend/content management update to the page.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check35 days agoChange DetectedThe page footer revision indicator was updated from v3.6.2 to v3.6.3. This reflects a new version of the page content and related updates.SummaryDifference0.1%

- Check42 days agoChange DetectedThe page footer revision label was updated from v3.6.0 to v3.6.2, indicating a newer release of the site software. This update reflects an underlying deployment refresh rather than changes to user-facing content.SummaryDifference0.1%

- Check56 days agoChange DetectedThe sponsor’s name and affiliated institution are now listed as separate items to improve attribution clarity, and new navigation/help links (How to Read a Study Record, Common Questions, How to Join a Study) along with a revised label for Intervention/Treatment and an updated revision stamp were added.SummaryDifference1%

- Check63 days agoChange DetectedThe page footer revision label was updated to v3.5.5, replacing the previous v3.5.4 and indicating a minor site/template update.SummaryDifference0.1%

- Check85 days agoChange DetectedRevision label on the page updated to v3.5.4, replacing the previous v3.5.3. This indicates a minor update to the page template or accompanying content.SummaryDifference0.1%

Stay in the know with updates to Yttrium90 Ipilimumab Nivolumab in Uveal Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Yttrium90 Ipilimumab Nivolumab in Uveal Melanoma Clinical Trial page.